Literature DB >> 22685168

Different expression of adrenoceptors and GRKs in the human myocardium depends on heart failure etiology and correlates to clinical variables.

Fermí Montó1, Eduardo Oliver, Diana Vicente, Joaquín Rueda, Jaime Agüero, Luis Almenar, Maria Dolores Ivorra, Domingo Barettino, Pilar D'Ocon.   

Abstract

Downregulation of β(1)- adrenergic receptors (β(1)-ARs) and increased expression/function of G-protein-coupled receptor kinase 2 (GRK2) have been observed in human heart failure, but changes in expression of other ARs and GRKs have not been established. Another unresolved question is the incidence of these compensatory mechanisms depending on heart failure etiology and treatment. To analyze these questions, we quantified the mRNA/protein expressions of six ARs (α(1A), α(1B), α(1D), β(1), β(2), and β(3)) and three GRKs (GRK2, GRK3, and GRK5) in left (LV) and right ventricle (RV) from four donors, 10 patients with ischemic cardiomyopathy (IC), 14 patients with dilated cardiomyopathy (DC), and 10 patients with nonischemic, nondilated cardiopathies (NINDC). We correlated the changes in the expressions of ARs and GRKs with clinical variables such as left ventricular ejection fraction (LVEF) and left ventricular end-systolic and left ventricular end-diastolic diameter (LVESD and LVEDD, respectively). The main findings were 1) the expression of the α(1A)-AR in the LV positively correlates with LVEF; 2) the expression of GRK3 and GRK5 inversely correlates with LVESD and LVEDD, supporting previous observations about a protective role for both kinases in failing hearts; and 3) β(1)-AR expression is downregulated in the LV and RV of IC, in the LV of DC, and in the RV of NINDC. This difference, better than an increased expression of GRK2 (not observed in IC), determines the lower LVEF in IC and DC vs. NINDC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22685168     DOI: 10.1152/ajpheart.01061.2011

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  24 in total

1.  RyR2R420Q catecholaminergic polymorphic ventricular tachycardia mutation induces bradycardia by disturbing the coupled clock pacemaker mechanism.

Authors:  Yue Yi Wang; Pietro Mesirca; Elena Marqués-Sulé; Alexandra Zahradnikova; Olivier Villejoubert; Pilar D'Ocon; Cristina Ruiz; Diana Domingo; Esther Zorio; Matteo E Mangoni; Jean-Pierre Benitah; Ana María Gómez
Journal:  JCI Insight       Date:  2017-04-20

2.  Adrenergic Polymorphisms and Survival in African Americans With Heart Failure: Results From A-HeFT.

Authors:  Amber E Johnson; Karen Hanley-Yanez; Clyde W Yancy; Anne L Taylor; Arthur M Feldman; Dennis M McNamara
Journal:  J Card Fail       Date:  2019-04-09       Impact factor: 5.712

3.  Activation of α1A -adrenoceptors desensitizes the rat aorta response to phenylephrine through a neuronal NOS pathway, a mechanism lost with ageing.

Authors:  Cristina Arce; Diana Vicente; Vanessa Segura; Nicla Flacco; Fermi Montó; Luis Almenar; Jaime Agüero; Joaquín Rueda; Francesc Jiménez-Altayó; Elisabet Vila; Maria Antonia Noguera; Pilar D'Ocon; Maria Dolores Ivorra
Journal:  Br J Pharmacol       Date:  2017-05-10       Impact factor: 8.739

Review 4.  The evolving impact of g protein-coupled receptor kinases in cardiac health and disease.

Authors:  Priscila Y Sato; J Kurt Chuprun; Mathew Schwartz; Walter J Koch
Journal:  Physiol Rev       Date:  2015-04       Impact factor: 37.312

5.  Chronic β1-adrenergic blockade enhances myocardial β3-adrenergic coupling with nitric oxide-cGMP signaling in a canine model of chronic volume overload: new insight into mechanisms of cardiac benefit with selective β1-blocker therapy.

Authors:  Danielle M Trappanese; Yuchuan Liu; Ryan C McCormick; Alessandro Cannavo; Gayani Nanayakkara; Marina M Baskharoun; Harish Jarrett; Felix J Woitek; D Michael Tillson; A Ray Dillon; Fabio A Recchia; Jean-Luc Balligand; Steven R Houser; Walter J Koch; Louis J Dell'Italia; Emily J Tsai
Journal:  Basic Res Cardiol       Date:  2014-12-06       Impact factor: 17.165

6.  Balancing GRK2 and EPAC1 levels prevents and relieves chronic pain.

Authors:  Huijing Wang; Cobi J Heijnen; Cindy T J van Velthoven; Hanneke L D M Willemen; Yoshihiro Ishikawa; Xinna Zhang; Anil K Sood; Anne Vroon; Niels Eijkelkamp; Annemieke Kavelaars
Journal:  J Clin Invest       Date:  2013-11-15       Impact factor: 14.808

Review 7.  Alpha-1-adrenergic receptors in heart failure: the adaptive arm of the cardiac response to chronic catecholamine stimulation.

Authors:  Brian C Jensen; Timothy D OʼConnell; Paul C Simpson
Journal:  J Cardiovasc Pharmacol       Date:  2014-04       Impact factor: 3.105

Review 8.  "Canonical and non-canonical actions of GRK5 in the heart".

Authors:  Christopher J Traynham; Jonathan Hullmann; Walter J Koch
Journal:  J Mol Cell Cardiol       Date:  2016-01-29       Impact factor: 5.000

Review 9.  Pathological cardiac hypertrophy: the synergy of adenylyl cyclases inhibition in cardiac and immune cells during chronic catecholamine stress.

Authors:  Gabriel Komla Adzika; Jeremiah Ong'achwa Machuki; Wenkang Shang; Hongjian Hou; Tongtong Ma; Lijuan Wu; Juan Geng; Xide Hu; Xianluo Ma; Hong Sun
Journal:  J Mol Med (Berl)       Date:  2019-05-06       Impact factor: 4.599

Review 10.  Noncanonical Roles of G Protein-coupled Receptor Kinases in Cardiovascular Signaling.

Authors:  Sarah M Schumacher; Walter J Koch
Journal:  J Cardiovasc Pharmacol       Date:  2017-09       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.